Serum microRNA-210 levels in different groups of chronic hepatitis B patients

Clinica Chimica Acta

Volumn 450, Issue , 2015, Pages 203-209

  Yu, Fujun ^a   Yang, Jianhuan ^b   Ouyang, Jinsheng ^a   Zheng, Yihu ^a   Chen, Bicheng ^a   Li, Guojun ^c   Lu, Zhongqiu ^a   Dong, Peihong ^a   Zheng, Jianjian ^a  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL AND YUYING CHILDREN S HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^c Second Hospital of Ningbo   (China)

Author keywords

Chronic hepatitis B; HBs antigen; HBV carrier; HBV DNA; MicroRNA 210

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; HEPATITIS B SURFACE ANTIGEN; MICRORNA; MICRORNA 210; BIOLOGICAL MARKER; MIRN210 MICRORNA, HUMAN; VIRUS ANTIGEN; VIRUS DNA;

ADULT; ARTICLE; BLOOD SAMPLING; CHRONIC HEPATITIS B; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; FEMALE; HEPATITIS B VIRUS; HETEROZYGOTE; HUMAN; INFECTION; INTERNATIONAL NORMALIZED RATIO; LIVER FIBROSIS; LIVER FUNCTION; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; VIRUS REPLICATION; VIRUS TRANSCRIPTION; BLOOD; GENETICS; HEPATITIS B; IMMUNOLOGY; INJURIES; LIVER; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK; VIROLOGY;

ADULT; ANTIGENS, VIRAL; BIOMARKERS; DISEASE PROGRESSION; DNA, VIRAL; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER; MALE; MICRORNAS; MIDDLE AGED; RISK; VIRUS REPLICATION;

EID: 84940513818     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2015.08.022     Document Type: Article

References (36)

1. Dienstag J.L. Hepatitis B virus infection. N. Engl. J. Med. 2008, 359:1486-1500.
2. McMahon B.J. Epidemiology and natural history of hepatitis B. Semin. Liver Dis. 2005, 25(Suppl. 1):3-8.
3. Liu X., Wan X., Li Z., Lin C., Zhan Y., Lu X. Golgi protein 73(GP73), a useful serum marker in liver diseases. Clin. Chem. Lab. Med. 2011, 49:1311-1316.
4. Chen C.J., Yang H.I., Su J., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA, J. Am. Med. Assoc. 2006, 295:65-73.
5. Croce C.M., Calin G.A. miRNAs, cancer, and stem cell division. Cell 2005, 122:6-7.
6. Esquela-Kerscher A., Slack F.J. Oncomirs - microRNAs with a role in cancer. Nat. Rev. Cancer 2006, 6:259-269.
7. Kloosterman W.P., Plasterk R.H. The diverse functions of microRNAs in animal development and disease. Dev. Cell 2006, 11:441-450.
8. Yu F., Guo Y., Chen B., Dong P., Zheng J. MicroRNA-17-5p activates hepatic stellate cells through targeting of Smad7. Lab. Invest. J. Techn. Methods Pathol. 2015, 10.1038/labinvest.2015.58.
9. Zhang G.L., Li Y.X., Zheng S.Q., Liu M., Li X., Tang H. Suppression of hepatitis B virus replication by microRNA-199a-3p and microRNA-210. Antivir. Res. 2010, 88:169-175.
10. Coppola N., Potenza N., Pisaturo M., et al. Liver microRNA hsa-miR-125a-5p in HBV chronic infection: correlation with HBV replication and disease progression. PLoS One 2013, 8.
11. Chen X., Ba Y., Ma L., et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008, 18:997-1006.
12. Fang C., Zhu D.X., Dong H.J., et al. Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphoma. Ann. Hematol. 2012, 91:553-559.
13. Gilad S., Meiri E., Yogev Y., et al. Serum microRNAs are promising novel biomarkers. PLoS One 2008, 3.
14. Mitchell P.S., Parkin R.K., Kroh E.M., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:10513-10518.
15. Huang C., Zheng J.M., Cheng Q., et al. Serum microRNA-29 levels correlate with disease progression in patients with chronic hepatitis B virus infection. J. Dig. Dis. 2014, 15:614-621.
16. Yu F., Zhou G., Li G., Chen B., Dong P., Zheng J. Serum miR-181b is correlated with hepatitis B virus replication and disease progression in chronic hepatitis B patients. Dig. Dis. Sci. 2015.
17. Ishak K., Baptista A., Bianchi L., et al. Histological grading and staging of chronic hepatitis. J. Hepatol. 1995, 22:696-699.
18. Yao J., Liang L., Huang S., et al. MicroRNA-30d promotes tumor invasion and metastasis by targeting Galphai2 in hepatocellular carcinoma. Hepatology 2010, 51:846-856.
19. Bihrer V., Friedrich-Rust M., Kronenberger B., et al. Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection. Am. J. Gastroenterol. 2011, 106:1663-1669.
20. Manesis E.K., Papatheodoridis G.V., Tiniakos D.G., et al. Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B. J. Hepatol. 2011, 55:61-68.
21. Brunetto M.R., Oliveri F., Colombatto P., et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010, 139:483-490.
22. Jaroszewicz J., Calle Serrano B., Wursthorn K., et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J. Hepatol. 2010, 52:514-522.
23. Degertekin B., Lok A.S. Indications for therapy in hepatitis B. Hepatology 2009, 49:S129-S137.
24. Ozer J., Ratner M., Shaw M., Bailey W., Schomaker S. The current state of serum biomarkers of hepatotoxicity. Toxicology 2008, 245:194-205.
25. Amacher D.E., Adler R., Herath A., Townsend R.R. Use of proteomic methods to identify serum biomarkers associated with rat liver toxicity or hypertrophy. Clin. Chem. 2005, 51:1796-1803.
26. Ebert M.P., Korc M., Malfertheiner P., Rocken C. Advances, challenges, and limitations in serum-proteome-based cancer diagnosis. J. Proteome Res. 2006, 5:19-25.
27. EASL Clinical practice guidelines: management of chronic hepatitis B. J. Hepatol. 2009, 50:227-242.
28. Russo A., Potenza N. Antiviral effects of human microRNAs and conservation of their target sites. FEBS Lett. 2011, 585:2551-2555.
29. Potenza N., Papa U., Mosca N., Zerbini F., Nobile V., Russo A. Human microRNA hsa-miR-125a-5p interferes with expression of hepatitis B virus surface antigen. Nucleic Acids Res. 2011, 39:5157-5163.
30. Zheng J., Zhou Z., Xu Z., et al. Serum microRNA-125a-5p, a useful biomarker in liver diseases, correlates with disease progression. Mol. Med. Rep. 2015, 12:1584-1590.
31. Murakami Y., Toyoda H., Tanaka M., et al. The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families. PLoS One 2011, 6.
32. Iloeje U.H., Yang H.I., Su J., Jen C.L., You S.L., Chen C.J. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006, 130:678-686.
33. Ho A.S., Huang X., Cao H., et al. Circulating miR-210 as a novel hypoxia marker in pancreatic cancer. Transl. Oncol. 2010, 3:109-113.
34. Lorenzen J.M., Kielstein J.T., Hafer C., et al. Circulating miR-210 predicts survival in critically ill patients with acute kidney injury. Clin. J. Am. Soc. Nephrol. 2011, 6:1540-1546.
35. Gee H.E., Camps C., Buffa F.M., et al. hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer 2010, 116:2148-2158.
36. Song G., Jia H., Xu H., et al. Studying the association of microRNA-210 level with chronic hepatitis B progression. J. Viral Hepat. 2014, 21:272-280.